Efficacy of combination therapy with angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertension

Bibliography

• Sliwa K, Stewart S, Gersh BJ. Hypertension: a global perspective. Circulation 2011;123:2892-6
   PubMed Web of Science ®Google Scholar
• Leone A, Landini L, Leone A. Epidemiology and costs of hypertension-related disorders. Curr Pharm Des 2011;17:2955-72
   Google Scholar
• Kearney PM, Whelton M, Reynolds K, Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
   PubMed Web of Science ®Google Scholar
• Kotchen TA. Hypertension control – trends, approaches, and goals. Hypertension 2007;49:19-20
   PubMed Web of Science ®Google Scholar
• Mulrow CD, Pignone M. What are the elements of good treatment for hypertension? BMJ 2001;322:1107-9
   PubMedGoogle Scholar
• Frijling BD, Spies TH, Lobo CM, Blood pressure control in treated hypertensive patients: clinical performance of general practitioners. Br J Gen Pract 2001;51:9-14
   PubMed Web of Science ®Google Scholar
• Primatesta P, Poulter NR. Hypertension management and control among English adults aged 65 years and older in 2000 and 2001. J Hypertens 2004;22:1093-8
   PubMed Web of Science ®Google Scholar
• Nesbitt SD. Antihypertensive combination therapy: optimizing blood pressure control and cardiovascular risk reduction. J Clin Hypertens 2007;9:26-32
   PubMedGoogle Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org
   Google Scholar
• Antman EM, Lau J, Kupelnick B, A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA 1992;268:240-8
   PubMed Web of Science ®Google Scholar
• Oxman AD, Guyatt GH. The science of reviewing research. Ann NY Acad Sci 1993;703:125-33. discussion 33-4
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
   PubMed Web of Science ®Google Scholar
• Ostergren J, Poulter NR, Sever PS, The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens 2008;26:2103-11
   PubMed Web of Science ®Google Scholar
• Dolan E, Stanton AV, Thom S, Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients–an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens 2009;27:876-85
   PubMed Web of Science ®Google Scholar
• Williams B, Lacy PS, Thom SM, Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25
   PubMed Web of Science ®Google Scholar
• Jamerson KA, Bakris GL, Wun CC, Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004;17:793-801
   PubMed Web of Science ®Google Scholar
• Weber MA, Bakris GL, Dahlof B, Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press 2007;16:13-19
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
   PubMed Web of Science ®Google Scholar
• Weber MA, Bakris GL, Jamerson K, Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010;56:77-85
   PubMed Web of Science ®Google Scholar
• Jamerson KA, Devereux R, Bakris GL, Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension 2011;57:174-9
   PubMed Web of Science ®Google Scholar
• Jamerson KA, Bakris GL, Weber MA. 24-hour ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med 2010;363:98
   Google Scholar
• Staessen JA, Fagard R, Thijs L, Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64
   PubMed Web of Science ®Google Scholar
• Thijs L, Richart T, de Leeuw PW, Morbidity and mortality on combination versus monotherapy: a post hoc analysis of the Systolic Hypertension in Europe trial. J Hypertens 2010;28:865-74
   Google Scholar
• Mancia G, De Backer G, Dominiczak A, 2007;ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007;25:1751-62
   PubMed Web of Science ®Google Scholar
• Klingbeil AU, Schneider M, Martus P, A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41-6
   PubMed Web of Science ®Google Scholar
• Davies JI, Struthers AD. Pulse wave analysis and pulse wave velocity: a critical review of their strengths and weaknesses. J Hypertens 2003;21:463-72
   PubMedGoogle Scholar